中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

First Patient Enrolled in Phase III Clinical Trial of Deunoxavir Marboxil (An Innovative Anti-Influenza Drug) for Pediatric Indication

Recently, the Phase III clinical trial for pediatric indication of Deunoxavir Marboxil, an innovative anti-influenza drug jointly developed by Simcere...

2024-09-13
Simcere Zaiming’s Pol θ inhibitor obtained IND approval from US FDA

On August 29, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that the i...

2024-09-04
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United Stated Food and Drug Administration

On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tab...

2024-09-03
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreeme...

2024-09-02
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.